ABBOTT PARK, Ill., April 9, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its TriClip™ Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in ...

ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip™ Transcatheter Tricuspid Valve Repair System, the ...

U.S. patients suffering from a leaky tricuspid valve, or tricuspid regurgitation (TR), have more treatment options than ever before, thanks to two significant FDA approvals. FDA has approved Abbott’s ...

Late-breaking data presented at American College of Cardiology Scientific Sessions (ACC.23) and simultaneously published in The New England Journal of Medicine demonstrate TriClip was superior to ...

Late-breaking data presented at EuroPCR in Paris, France this week supports the benefits of Abbott's TriClip transcatheter edge-to-edge repair (TEER) system in treating patients with leaky tricuspid ...

TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery More than 1.6 million people in the U.S.

Northwell Health, in Manhasset, NY, was an enrolling site for the TRILUMINATE pivotal trial of TriClip (Abbott), and for Northwell cardiologist Bruce Rutkin, MD, the commercial availability of the ...

Stopping leaks in the heart’s tricuspid valve has been a notoriously tricky fix, but, now, the FDA is handing out its second approval for a dedicated, minimally invasive therapy in as many months.

Abbott Laboratories, of Abbott Park, Ill., reported that its Triclip transcatheter tricuspid valve repair system has received the CE mark. The device is a nonsurgical treatment for people with ...

Abbott Laboratories Inc. reported 30-day results from its Triclip Bright Study at the EuroPCR meeting in Paris on May 19. The real-world outcomes showed that the company’s tricuspid repair systems ...